Kai Masayuki

カイマサユキ | Kai Masayuki

Affiliation and department：
Job title： Vice President, Head of Research
Papers (12)：

Yuta Tezuka, Naoki Onoda, Tatsuya Morishima, Yoshiki Sumitomo, Keigo Nishii, Hitoshi Takizawa, Masayuki Kai. Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag. International journal of hematology. 2024
Yuta Izumi, Masashi Kanayama, Zhongchuzi Shen, Masayuki Kai, Shunsuke Kawamura, Megumi Akiyama, Masahide Yamamoto, Toshikage Nagao, Keigo Okada, Norihiko Kawamata, et al. An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy. Frontiers in immunology. 2021. 12. 618081-618081
Yoshiyuki Kiyasu, Kenji Kawada, Hideyo Hirai, Ryotaro Ogawa, Keita Hanada, Hideyuki Masui, Gen Nishikawa, Takamasa Yamamoto, Rei Mizuno, Yoshiro Itatani, et al. Disruption of CCR1-mediated myeloid cell accumulation suppresses colorectal cancer progression in mice. Cancer letters. 2020. 487. 53-62
泉湧太, 金山剛士, 秋山めぐみ, 甲斐正之, 沈鐘楚子, 川又紀彦, 樗木俊聡. 単球性白血病の新規治療戦略としての単球系制限抗原の標的化(Targeting monocyte lineage-restricted antigen as a novel therapeutic strategy for monocytic leukemia). 日本病理学会会誌. 2020. 109. 1. 304-304
Ved P Sharma, Robert Eddy, David Entenberg, Masayuki Kai, Frank B Gertler, John Condeelis. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Current biology : CB. 2013. 23. 21. 2079-89

ｍore...

MISC (4)：

泉湧太, 金山剛士, 秋山めぐみ, 甲斐正之, 沈鐘楚子, 川又紀彦, 樗木俊聡. 単球性白血病の新規治療戦略としての単球系制限抗原の標的化(Targeting monocyte lineage-restricted antigen as a novel therapeutic strategy for monocytic leukemia). 日本病理学会会誌. 2020. 109. 1. 304-304
In vivo efficacy of anti-MPL agonist antibody for human hematopoietic cells. 2009. 59. 1. 73-77
Anti-thrombopoietin receptor whole-IgG agonist antibodies improved by domain-subclass conversion. Bio industry. 2008. 25. 7. 83-91
Masayuki Kai, Kazuhiro Motoki, Hideaki Yoshida, Kumi Tsuruhata, Chisato Endo, Mari Muto, Chie Emuta, Yukiko Chisaka, Munetake Shimabe, Hiroshi Miyazaki, et al. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG. BLOOD. 2006. 108. 11. 336A-337A

Patents (13)：

ｍore...

Books (1)：

Lectures and oral presentations (2)：

Hematopoietic stem cell-based cell and gene therapy beyond monogenic diseases
(UC San Diego inaugural Gene Therapy Initiative Symposium 2024)
Anti-thrombopoietin receptor agonist antibodies improved by domain-sublcass conversion
(The 14th international Conference on Human Antibodies & Hybridomas 2008)

Professional career (1)：

Work history (4)：

2024/01 - 現在 Kyowa Kirin, Inc. - U.S. Vice President, Head of Research
2004/04 - 現在 Kyowa Kirin Co., Ltd.
2023/10 - 2023/12 Kyowa Kirin, Inc. - U.S. Executive Director of Research
2010/06 - 2011/11 Massachusetts Institute of Technology Koch Institute of Integrated Cancer Research Visiting Scientist

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page